| Bioactivity | FGFR4-IN-20 (comp 11) is an orally active and selective FGFR4 inhibitor with IC50s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research[1]. |
| Invitro | FGFR4-IN-20 (0.01-1000 nM) 对 Huh7 (FGFR 过表达)，Hep3B (FGF19 处理) 和 JHH-7 (FGF19 处理) 细胞系的 IC50 分别为 19, 16 和 33 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> FGFR4-IN-20 相关抗体: |
| In Vivo | FGFR4-IN-20 (100mg/kg, p.o., QD for 15 d) 显著缩小 ICR 小鼠的肿瘤体积，而没有显示出体重减轻或其他临床体征[1]。1.19FGFR4-IN-20 在 ICR 小鼠中的药代动力学特征[1]Parameter |
| Formula | C26H22Cl2N4O3 |
| Molar Mass | 509.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Oh H, et al. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma. J Med Chem. 2024 May 23;67(10):8445-8459. |